Septodont to Market Sprix Nasal Spray

Septodont, the Lancaster, Pennsylvania-based manufacturer of dental anesthetics, has signed an agreement with Egalet for exclusive rights to market Sprix Nasal Spray (ketorolac tromethamine) to U.S. clinicians. The spray is indicated as an alternative to opioid or steroid therapy. It is a short-term treatment, which can be prescribed to adults for up to five days, to manage moderate to moderately severe pain that would otherwise require opioid-level analgesia.